Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | GCK | P35557 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23999891 | 0.85 | NR4A1 (0.61) | GRM2NR4A1DYRK1AALDH1A1UHRF1 | |
| SCHEMBL4794755 | 0.83 | NR4A1 (0.44) | GRM2NR4A1DYRK1AALDH1A1UHRF1 | |
| SCHEMBL12907980 | 0.83 | GRM2 (0.43) | GRM2DYRK1AUHRF1PPARGDRD1 | |
| SCHEMBL1137172 | 0.83 | NOS3 (0.50) | NR4A1DYRK1AALDH1A1MAPK14NOS3 | |
| SCHEMBL2028918 | 0.81 | LOX (0.41) | NR4A1DYRK1AALDH1A1MAPK14NOS3 | |
| SCHEMBL29834758 | 0.81 | NR4A1 (0.41) | NR4A1ALDH1A1MAPK14NOS3NOS1 | |
| SCHEMBL573471 | 0.81 | NR4A1 (0.41) | NR4A1ALDH1A1MAPK14PPARGSOS1 | |
| SCHEMBL3654965 | 0.81 | EGFR (0.45) | GRM2DYRK1AUHRF1PPARGSOS1 | |
| SCHEMBL29834775 | 0.81 | NR4A1 (0.41) | NR4A1ALDH1A1MAPK14PPARGSOS1 | |
| SCHEMBL863328 | 0.80 | NR4A1 (0.61) | NR4A1ALDH1A1SOS1MAP4K4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022261352-A1 | PERFLUOROALKANE SUBSTITUTED PYRAZOLO[3,4-D]PYRIMIDIN AND PYRROLO[2,3-D]PYRIMIDIN COMPOUNDS AND USES THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20150175545-A1 | Preparation Method of Fluoro-Substituted Deuterated Diphenylurea | SUZHOU ZELGEN BIOPHARMACEUTICAL CO LTD (CN) | 2015-06-25 | — | — | US | disclosed |
| US-8759531-B2 | Preparation method of fluoro-substituted deuterated diphenylurea | Suzhou Zelgen Biopharmaccceutical Co., Ltd. (CN) | 2014-06-24 | — | — | US | disclosed |
| EP-1973897-B1 | Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders | BAYER IP GMBH (DE) | 2014-05-21 | — | — | EP | disclosed |
| US-8580798-B2 | Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20130060043-A1 | PREPARATION METHOD OF FLUORO-SUBSTITUTED DEUTERATED DIPHENYLUREA | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD (CN) | 2013-03-07 | — | — | US | disclosed |
| US-8207166-B2 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207166-B2 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207166-B2 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer | BAYER HEALTHCARE LLC (US) | 2012-06-26 | — | — | US | disclosed |
| EP-1751139-B1 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20100081812-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
| WO-2008140895-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080269267-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | US | disclosed |
| EP-1973897-A2 | SUBSTITUTED PYRYMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer HealthCare AG (DE) | 2008-10-01 | — | — | EP | disclosed |
| US-20080214545-A1 | Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer | BAYER HEALTHCARE LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080214545-A1 | Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer | BAYER HEALTHCARE LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080214545-A1 | Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer | BAYER HEALTHCARE LLC | 2008-09-04 | — | — | US | disclosed |
| WO-2007075650-A2 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER HEALTHCARE AG (DE) | 2007-07-05 | — | — | WO | disclosed |
| EP-1751139-A2 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Bayer Pharmaceuticals Corporation (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005110994-A2 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214545-A1 | Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer | UMPS, SLC14A1, TP53 | GRM2 4630/4885NR4A1 2500/4885DYRK1A 4751/4885 |
| US-20080269267-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | BRAF, RET, KIT | GRM2 1677/4885NR4A1 2643/4885DYRK1A 658/4885 |
| US-20130060043-A1 | PREPARATION METHOD OF FLUORO-SUBSTITUTED DEUTERATED DIPHENYLUREA | CCND3, UBE2D3, VDR | GRM2 2648/4885NR4A1 1479/4885DYRK1A 1051/4885 |
| US-20150175545-A1 | Preparation Method of Fluoro-Substituted Deuterated Diphenylurea | CCND3, UBE2D3, VDR | GRM2 2648/4885NR4A1 1479/4885DYRK1A 1051/4885 |
| US-20100081812-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | TYMP, DPYD, TYMS | GRM2 3717/4885NR4A1 1122/4885DYRK1A 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.